Catalent Biologics Invests $50 Million to Add Third High-Speed Vial Line at its Bloomington, Indiana, Facility
The new line is expected to be operational by April 2021 and will add capacity to support the growing pipeline of clinical programs and...
Put your AAV on the Fast-Track to the Clinic
Summary: In this executive summary, Catalent Cell & Gene Therapy experts George Buchman, Ph.D., Research Fellow, and Bhargavi Kondragunta,...
Bio Process International East
Each year, more than 3200+ bioprocessing professionals representing 40+ countries attend BioProcess International in Boston to learn about...



